Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma

Acta Medica Austriaca

Volumn 30, Issue 2, 2003, Pages 41-47

  Mikosch, P ^a   Gallowitsch, H J ^a   Zinke Cerwenka, W ^b   Heinisch, M ^a   Pipam, W ^a   Eibl, M ^b   Kresnik, E ^a   Unterweger, O ^a   Linkesch, W ^b   Lind, P ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Fluorine 18 fluorodeoxyglucose; Hodgkin's disease; Non Hodgkin lymphoma; Positron emission tomography; Restaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; MUSCLE RELAXANT AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; ECHOGRAPHY; HODGKIN DISEASE; HUMAN; INFLAMMATION; LYMPHOMA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUSCLE METABOLISM; MUSCLE RELAXATION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SECOND CANCER; WHOLE BODY SCANNER; ADOLESCENT; ADULT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; LABORATORY DIAGNOSIS; LYMPH NODE; MALE; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038018234     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2003.03003.x     Document Type: Article

References (23)

1. Adams S, Nickel E, Hör G: Differentialdiagnostische Problematik bei der Beurteilung von mediastinalen und pulmonalen Herden mittels F-18-FDG-PET. Nuklearmedizin 2000;39:83-84.
2. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Nergmann L: Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804.
3. Carr R, Barrington SF, Madan B, O'Doberty MJ, Saunders CAB, van der Walt J, Timothy AR: Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-3346.
4. Cremerius U, Fabry U, Kroll U, Zimny M, Neuerburg J, Osieka Büll U: Clinical value of FDG PET for therapy monitoring of malignant lymphoma - results of a retrospective study in 72 patients. Nuklearmedizin 1999;38:24-30.
5. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Büll U: Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-1063.
6. Delbeke D: Oncological application of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999;40:591-603.
7. De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK: Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8 (Suppl 1):57-60.
8. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME: Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-348.
9. Jacobsson H, Celsing F, Ingvar M, Stone-Elander S, Larson SA: Accumulation of FDG in axillary sweat glands in hyperhidrosis: a pitfall in whole-body PET examination. Eur Radiol 1998;8:482-483.
10. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than computed tomography scan imaging. Blood 1999;94:429-433.
11. Kostakoglu L, Yeh SD, Portlock C, Heelan R, Jao TJ, Niedzwiecki D, Larson SM: Validation of gallium-67-citrate single photon computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992;33:345-350.
12. Lorenzen J, de Witt M, Buchert R, Igel B, Bohuslavizki KH: Granulation tissue. Pitfall in therapy control with F-18-FDG PET after chemotherapy. Nuklearmedizin 1999;38:333-336.
13. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11 (Suppl 1):147-150.
14. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-609.
15. Moog F, Kotzerke J, Reske SN: FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407-1413.
16. Paul R: Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-292.
17. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, Enne C, Herz M, Ned C, Garbrecht M, Schwaiger M: Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-4471.
18. Sandrock D, Lastoria S, Magrath IT, Neumann RD: The role of gallium-67 tumor scintigraphy in patients with small, non-cleaved cell lymphoma. Eur J Nucl Med 1993;20:119-122.
19. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK: Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-728.
20. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J: False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 1997;38:888-890.
21. Willkomm P, Palmedo H, Grünwald F, Ruhlmann J, Biersack HJ: Functional imaging of Hodgkin's disease with FDG-PET and gallium-67. Nuklearmedizin 1998;37:251-253.
22. Wylie BR, Southee AE, Joshua DE, McLaughlin AF, Gibson J, Hutton BF, Morris JG, Kronenberg H: Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989;49:344-347.
23. Zinke-Cerwenka W, Eibl M, Lind P, Linkesch W: The clinical relevance of whole-body FDG-positron emission tomography for staging in patients with lymphoma and Hodgkin's disease. Onkologie 1999; 22 (Suppl 1): 152 (Abstract).